Christopher A. Eide

Also affiliated with OHSU Knight Cancer Institute

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins”.

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

Proceedings of the National Academy of Sciences(2013)10.1073/pnas.1319583110

N/A

0.716DataRank · unranked

117 citations

Anna Saborowski, Christopher A. Eide, Cristina Tognon, Rebecca L. Smith, Johannes Elferich +6 more

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Cancer Cell(2022)10.1016/j.ccell.2022.07.002

N/A

0DataRank · unranked

373 citations

Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson +89 more

Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism

Clinical and Translational Medicine(2022)10.1002/ctm2.1146

N/A

0DataRank · unranked

17 citations

Idaly M. Olivas, Alfonso E. Bencomo‐Alvarez, Andres J. Rubio, Christian Barreto‐Vargas, José López +25 more

Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B

Oncogene(2021)10.1038/s41388-021-01732-6

N/A

0DataRank · unranked

41 citations

Andres J. Rubio, Idaly M. Olivas, Mayra A. Gonzalez, Rebecca A. Ellwood, Carme Ripoll Fiol +12 more

CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102526

N/A

0DataRank · unranked

1 citations

Jessica Gibbs, Kevin Watanabe‐Smith, Ariel H. Nguyen, Isabel Kenna, Karina Thiel-Klare +12 more

A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.10.08.681215

N/A

0DataRank · unranked

0 citations

Christopher A. Eide, Andy Kaempf, Nicola Long, Alexandria Miller, Daniel Bottomly +8 more

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Cancer Cell(2024)10.1016/j.ccell.2024.08.004

N/A

0DataRank · unranked

15 citations

Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L. Savage, Serena Muratcioğlu +11 more